Innovent Biologics Showcases “Dual Innovations” at Oncology R&D Day, Pioneering …

🗝️ Key Points

• Innovent Biologics (IVBIY, Financial) hosted its Oncology R&D Day, focusing on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies.
• The company aims to advance at least five pipeline assets into MRCT Phase 3 by 2030, featuring a robust pipeline of nearly ten next-generation molecules.
• Its flagship product, IBI363, has shown significant survival benefits in hard-to-treat tumors, receiving multiple regulatory designations.

• Innovent Biologics (IVBIY, Financial) hosted its Oncology R&D Day, focusing on dual innovation in next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) technologies.
• The company aims to advance at least five pipeline assets into MRCT Phase 3 by 2030, featuring a robust pipeline of nearly ten next-generation molecules.
• Its flagship product, IBI363, has shown significant survival benefits in hard-to-treat tumors, receiving multiple regulatory designations.

Innovent Biologics (IVBIY) recently held its Oncology R&D Day, unveiling a strategic focus on dual innovation with next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) platforms. The event, which drew over 500 participants, highlighted the company’s ambitious plan to advance at least five pipeline assets into global MRCT Phase 3 by 2030, underscoring its commitment to pioneering new standards in cancer treatment.

The company’s flagship product, IBI363, a first-in-class PD-1/IL-2?-bias fusion protein, demonstrated breakthrough potential in treating hard-to-treat tumors, with median overall survival benefits of up to 17.5 months in NSCLC, 16.1 months in CRC, and 14.7 months in melanoma. IBI363 has received two Breakthrough Therapy Designations from the NMPA CDE and two Fast Track Designations from the FDA.

Innovent’s pipeline includes nearly ten next-generation molecules under global development, supported by R&D hubs in Shanghai and San Francisco and a manufacturing capacity for antibodies and ADCs exceeding 140,000L. Key candidates include IBI343 (CLDN18.2 ADC), IBI3009 (DLL3 ADC), IBI3003 (a tri-specific T-cell engager), IBI3001 (EGFR/B7H3 ADC), and IBI3020 (CEACAM5 dual-payload ADC).

MORE IN INSIDE INVESTMENT NEWS

Levi Strauss raises sales guidance, says it will absorb some tariff costs for now

Published: Thursday, July 10, 2025 · 8:52 PM

Delta shares jump 11% after airline reinstates 2025 profit outlook as CEO says bookings stabilized

Published: Thursday, July 10, 2025 · 1:54 PM